Alpha Tau Medical, developer of a breakthrough alpha-radiation cancer therapy, has initiated new clinical trials evaluating the efficacy of their Alpha DaRT or “Dіffusіng Alpha-emitters Radіatіon Therapy” with two leading medical centers in Rome, Italy.
“Building on our recent successful round of $29 Million in private financing, led by Shavit Capital, OurCrowd and Medison Ventures, we are delighted to further expand Alpha DaRT’s international clinical trials program with new protocols and indications,” said Uzi Sofer, Alpha Tau’s CEO. “This supports our mission to perform multiple clinical studies for different indications across the globe and build local production facilities to enable optimized local manufacturing and distribution. This will help us rapidly bring to market our new Alpha DaRT cancer treatment approach and save lives.”
The trials follow the approval from the Institutional Review Board (IRB). La Sapienza is initiating Alpha Tau’s clinical trial protocol for SCC of the Skin and Oral Cavity, and IFO is conducting their first study of Alpha DaRT for the treatment of CMN.
Alpha DaRT is said to enable the first alpha-radiation-based cancer treatment for all types of solid tumors. The team hopes that the study’s outcome will further reinforce the promising early results from the ongoing SCC study at the Rabin Medical Center, Israel and the IRST, Italy. Results showed all patients’ tumor sizes reduced and more than 70% of patients’ tumors completely disappeared within a few weeks after treatment.
In September, Alpha Tau Medical announced that it had secured $29 million in private financing led by Shavit Capital, alongside OurCrowd, Medison Ventures, and other current investors.
OurCrowd, the largest investment crowdfunding platform in the world, has selected Medtech / Healthtech as an area of focus.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!